ROSUVASTATIN CALCIUM (rosuvastatin calcium) by Fosun Pharma is hmg-coa reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme a to mevalonate, a precursor of cholesterol. First approved in 2016.
Drug data last refreshed 12h ago
HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Pharmacokinetic Effect of Y-3 for Injection on Rosuvastatin Calcium Tablets in Healthy Participants
Study to Evaluate the Bioequivalence of "Crecheck Tablet 2.5 mg (Rosuvastatin Calcium)" and "Crestor Tablet 5 mg (Rosuvastatin Calcium)" in Healthy Adult Subjects
Rosuvastatin Calcium Bioequivalence Study - Fast
Evaluating a Pharmacokinetic Drug Interaction Between Metformin Hydrochloride and Rosuvastatin Calcium
Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium
Worked on ROSUVASTATIN CALCIUM at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.